GIM
NVS icon

Glenmede Investment Management’s Novartis NVS Stock Holding History

Glenmede Investment Management’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$5.8M Buy
45,234
+18,897
+72% +$2.31M 0.03% 423
2025
Q2 		$3.19M Buy
+26,337
New +$2.97M 0.02% 507

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Glenmede Investment Management's NVS Position: Q3 2025 in Review

Glenmede Investment Management increased its Novartis (NVS) stake by 72% in Q3 2025, buying an estimated $2.31M and bringing the position to 45,234 shares worth $5.8M. The position accounts for 0.03% of the portfolio, ranked #423.

Glenmede Investment Management first reported a position in NVS in Q2 2025 and has held it in 2 quarters since. 1,400 funds tracked by Wall St. Rank hold NVS as of Q3 2025.

  • Glenmede Investment Management held 45,234 shares of Novartis worth $5.8M as of Q3 2025.
  • Glenmede Investment Management bought 18,897 Novartis shares in Q3 2025, an estimated $2.31M.
  • Novartis made up 0.03% of Glenmede Investment Management's portfolio in Q3 2025, its #423 holding.
  • Glenmede Investment Management first reported a position in Novartis in Q2 2025 and has held it in 2 quarters since.
  • 1,400 funds tracked by Wall St. Rank held Novartis as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.